Compare BioNano Genomics Inc (BNGO) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Huntington Bancshares Incorporated — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Huntington Bancshares Incorporated trades at $18.14 (market cap $36.18B). The key difference: Huntington Bancshares Incorporated is far larger — about 2740.9× BioNano Genomics Inc's market cap, and Huntington Bancshares Incorporated pays a 3.47% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | HBAN | |
|---|---|---|
Market Cap | $13.20M | $36.18B |
Sector | Health | Financials |
52-Week High | $4.92 | $19.27 |
52-Week Low | $1.09 | $15.02 |
Enterprise Value | $15.81M | — |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Huntington Bancshares (HBAN) trades at $17.93, up 0.34% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 EPS of $0.25, beating expectations, and maintains a net income margin of 25.13%. Recent news highlights expansion in Texas and a fintech partnership award. Analyst consensus is a Buy with a $20.25 price target, suggesting potential upside.
HBAN presents a favorable outlook with earnings growth potential, supported by strategic acquisitions and solid fundamentals. Risks include integration challenges from recent M&A and competitive pressures in regional banking. The stock's current valuation below consensus target indicates room for appreciation, though investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
